Soligenix (STU:DOA) Current Accrued Expense : €2.39 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Soligenix Current Accrued Expense?

Soligenix's Current Accrued Expense for the quarter that ended in Mar. 2024 was €2.39 Mil.

Soligenix's quarterly Current Accrued Expense declined from Sep. 2023 (€2.24 Mil) to Dec. 2023 (€2.22 Mil) but then increased from Dec. 2023 (€2.22 Mil) to Mar. 2024 (€2.39 Mil).

Soligenix's annual Current Accrued Expense declined from Dec. 2021 (€2.62 Mil) to Dec. 2022 (€2.18 Mil) but then increased from Dec. 2022 (€2.18 Mil) to Dec. 2023 (€2.22 Mil).

Soligenix Current Accrued Expense Historical Data

The historical data trend for Soligenix's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Current Accrued Expense Chart

Soligenix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

2.84

2.17

2.62

2.18

2.22

Soligenix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															2.29	2.17	2.24	2.22	2.39

Soligenix Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Soligenix Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Soligenix's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (STU:DOA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

SNGX:USA

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines